Topics / Weight, GLP-1 & Metabolic Therapy
Focus area
Weight, GLP-1 & Metabolic Therapy
Evidence you can trust. Clinical questions you care about.
GLP-1 outcomes, muscle preservation, weight regain, and incretin safety questions.
Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026
7 published deep analyses
Featured evidence questions
Top clinical questions
High-priority clinical questions with structured evidence analysis in this focus area.
Do GLP-1 receptor agonists reduce major
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open deep analysis →
How does tirzepatide compare with semaglutide
How does tirzepatide compare with semaglutide for weight loss?
Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.
Open deep analysis →
Do patients regain weight after stopping
Do patients regain weight after stopping GLP-1 therapy?
Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.
Open deep analysis →
Does GLP-1 treatment cause meaningful muscle
Does GLP-1 treatment cause meaningful muscle loss?
GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.
Open deep analysis →
Published deep analyses
Evidence map
All published structured analyses in this focus area, with core studies and explainable confidence.
Do GLP-1 receptor agonists reduce major
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open deep analysis →
Do patients regain weight after stopping
Do patients regain weight after stopping GLP-1 therapy?
Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.
Open deep analysis →
How does tirzepatide compare with semaglutide
How does tirzepatide compare with semaglutide for weight loss?
Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.
Open deep analysis →
Does GLP-1 treatment cause meaningful muscle
Does GLP-1 treatment cause meaningful muscle loss?
GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.
Open deep analysis →
Do GLP-1 agonists increase pancreatitis risk
Do GLP-1 agonists increase pancreatitis risk?
Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.
Open deep analysis →
Do GLP-1 drugs increase thyroid cancer
Do GLP-1 drugs increase thyroid cancer risk in humans?
Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.
Open deep analysis →
Can resistance training and protein intake
Can resistance training and protein intake preserve muscle during GLP-1 weight loss?
Exercise and higher protein intake are biologically plausible strategies to attenuate lean mass loss during significant GLP-1-mediated weight reduction, though dedicated outcome trials are still emerging.
Open deep analysis →
Latest evidence
Recent core studies
Recently published studies linked to evidence analyses in this focus area.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2026
Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.
View study →
Indian journal of pharmacology · 2026
Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.
View study →
Diabetes, obesity & metabolism · 2025
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
View study →
Related topics
Explore adjacent focus areas
Explore another focus area or ask a new clinical question grounded in published evidence.